GOFLA REPORT AT THE OUTPATIENT DEPARTMENT - TAM DUC HEART HOSPITAL

On June 26, 2026, Medbolide Pharma attended a scientific seminar organized by the Outpatient Department at Tam Duc Heart Hospital. The seminar was attended by doctors and nurses from the department and was chaired by the Department Head, M.D., M.S. Ngo Thi Kim Anh.

At the meeting, Dr. Ngo Thi Kim Anh, M.S., shared information about GOFLA (Apixaban 2.5 mg)—a factor Xa inhibitor and a new-generation anticoagulant used to treat, prevent recurrence, and halt the further development of blood clots—with the following key features:

• Reduces stroke and vascular thromboembolism—superior to VKAs in patients with non-valvular atrial fibrillation
• Most effective in preventing VTE after hip and knee replacement surgery
• Recommended as the best anticoagulant for patients with end-stage chronic kidney disease by the ACC/AHA/ACCP/HRS 2023 guidelines; for patients ≧ 65 years of age by the American Geriatrics Society 2023 guidelines

The presentation attracted the attention and praise of the doctors regarding the GOFLA 2.5 product.

At the end of the session, the company expressed its gratitude and hope to continue partnering with the hospital in providing effective solutions to improve the quality of patient care. Medbolide Pharma is proud to be a trusted partner of Tam Duc Heart Hospital in supplying high-quality, effective medical products that contribute to the healthcare of the community.